Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Plus Dutasteride/Finasteride in Vulnerable Elderly Prostate Cancer
NCT02213107Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Sep 2014
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by University of Rochester. Primary endpoint: Prostate Specific Antigen Progression Free Survival at 3 years. Started Sep 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02213107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213107.